ArticleCureus2025
Cardiovascular Risk Among Patients With Moderate-to-Severe Plaque Psoriasis in Southern Sri Lanka: A Case-Control Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriasis is a chronic inflammatory skin condition associated with increased cardiovascular (CV) risk and a higher prevalence of comorbidities. The study aimed to assess CV risk and contributory factors in patients with chronic plaque psoriasis (CPP).
methodsThis case-control study included 80 patients with CPP attending selected dermatology clinics in Southern Sri Lanka, along with 80 age- and sex-matched controls from their neighbourhood. Data on demographic and disease-related factors were collected using an interviewer-administered questionnaire from consecutive patients with moderate to severe psoriasis, as defined by body surface area (BSA) and the Psoriasis Area and Severity Index (PASI). Anthropometric measurements, blood glucose, and lipid assays were conducted for both groups. Comorbidity was assessed using the Charlson Comorbidity Index (CCI) while CV risk was estimated using the Framingham Risk Score (FRS) and the Atherosclerotic Cardiovascular Disease (ASCVD) 10-year risk score.
resultsMean (standard deviation, or SD) age of patients with CPP (n=80) was 51 (11) years, with 41 being male. The corresponding values of controls were 50 (10) years, with 41 being male. The median (interquartile range, or IQR) duration of psoriasis was 10 (6-20) years, median (IQR) BSA was 11.3% (5.5-20.4%), and median (IQR) PASI was 6.7 (5.3-10.8). Patients with psoriasis had a higher median CCI value (1 (1-3) vs. 0 (1-2); U=1819, p < 0.001) and higher occurrence of dyslipidaemia (odds ratio (OR) 5.69; confidence interval (CI): 2.03-15.93) compared to controls. Patients with CPP had higher triglycerides (TG) and triglyceride-to-high-density lipoprotein (TG/HDL) ratios compared to controls (p < 0.05 for both). Although CV risk scores were higher among patients with CPP, they did not differ significantly from those of controls.
conclusionPatients with CPP have higher comorbidity and unadjusted lipid levels. This highlights the need to educate healthcare professionals to adopt a more holistic approach in evaluating patients with CPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.